Translational Medicine and Clinical Pharmacology Publications

  • Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcription.

    Pellanda P.; Dalsass M.; Filipuzzi M.; et al. The EMBO journal 2021; 40 (10) .

    Read abstract
  • Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.

    Pearson A.D.; DuBois S.G.; Buenger V.; et al. European journal of cancer (Oxford, England : 1990) 2021; 146 : 115-124.

    Read abstract
  • In-depth transcriptomic analysis of human retina reveals molecular mechanisms underlying diabetic retinopathy.

    Becker K; Klein H; Simon E; et al. Scientific reports 2021; 11 (1) : 10494.

    Read abstract
  • A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.

    Johnston CK; Eudy-Byrne RJ; Elmokadem A; et al. Pharmaceutics 2021; 13 (4) .

    Read abstract
  • IL36 is a critical upstream amplifier of neutrophilic lung inflammation in mice.

    Koss C.K.; Wohnhaas C.T.; Baker J.R.; et al. Communications Biology 2021; 4 (1) : 172.

    Read abstract
  • Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.

    Hundertmark M.J.; Agbaje O.F.; Coleman R.; et al. ESC Heart Failure 2021; .

    Read abstract
  • RORgammat inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma.

    Lamb, David; De Sousa D; Quast K; et al. Respiratory research 2021; 22 (1) : 158.

    Read abstract
  • Comparison of Four fMRI Paradigms Probing Emotion Processing.

    Hartling C; Metz S; Pehrs C; et al. Brain Sciences 2021; 11 (5) .

    Read abstract
  • Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma (Investigational New Drugs, (2020), 38, 5, (1472-1482), 10.1007/s10637-020-00916-3).

    Kroschinsky F.; Middeke J.M.; Janz M.; et al. Investigational new drugs 2021; 39 (1) : 285-286.

    Read abstract
  • Exosomal mirnas as potential biomarkers to monitor phosphodiesterase 5 inhibitor induced anti-fibrotic effects on CCl4 treated rats.

    Broermann, Andre; Schmid, Ramona; Gabrielyan O.; et al. International Journal of Molecular Sciences 2021; 22 (1) : 1-22.

    Read abstract
  • Extensive histopathological characterization of inflamed bowel in the dextran sulfate sodium mouse model with em-phasis on clinically relevant biomarkers and targets for drug development.

    Bonfiglio R.; Galli F.; Varani M.; et al. International Journal of Molecular Sciences 2021; 22 (4) : 1-20.

    Read abstract
  • Basophil activation test: Assay precision and BI 1002494 SYK inhibition in healthy and mild asthmatics.

    Carstensen S.; Benediktus E; Litzenburger, Tobias; et al. CYTOMETRY PART A 2021; .

    Read abstract
  • Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.

    Schmid U; Weber BE; Magnusson M.O.; et al. Respiratory medicine 2021; 180 : 106369.

    Read abstract
  • Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study.

    Mrowietz U.; Burden A.D.; Pinter A.; et al. Dermatology and Therapy 2021; 11 (2) : 571-585.

    Read abstract
  • Pilot study of an occupational healthcare program to assess the SARS-CoV-2 infection and immune status of employees in a large pharmaceutical company.

    Moroni-Zentgraf Petra; Keller C.; Mahmoudi M.; et al. Current medical research and opinion 2021; 37 (6) : 939-947.

    Read abstract
  • FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD.

    Crapo J; Gupta A; Lynch DA; et al. BMJ Open 2021; 11 (3) : e042526.

    Read abstract
  • First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers.

    Mackie A; Rascher J.; Schmid M; et al. 2021; 7 (1) : 1-13.

    Read abstract
  • Single-dose effects of Citalopram on neural responses to affective stimuli in borderline personality disorder: A randomized clinical trial.

    Paret C; Niedtfeld I; Lotter T; et al. 2021; .

    Read abstract
  • Effect of itraconazole on the pharmacokinetics of faldaprevir in healthy subjects.

    Huang, Fenglei; Marzin K; Koenen RR; et al. 2021; 76 (5) : 189-194.

    Read abstract
  • Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.

    Deterding R; Griese M; Deutsch G; et al. 2021; 7 (2) .

    Read abstract